Which Frontline EGFR TKI Should be Used in NSCLC?
Lecia V. Sequist, MD, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.
Clinical Pearls
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.
- Patients with EGFR-mutated NSCLC should preferentially receive an EGFR TKI, not chemotherapy.
- It is still unknown which EGFR TKI should be administered first.
- A trial is underway comparing gefitinib with afatinib in the frontline setting.
Recent Videos
Related Content
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024Article
In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
